Welcome to our dedicated page for SANUWAVE Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SANUWAVE Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SANUWAVE Health's regulatory disclosures and financial reporting.
Opaleye Management Inc., Opaleye, L.P., and James Silverman report beneficial ownership of SANUWAVE Health, Inc. common stock on an amended Schedule 13G. The reporting persons are deemed to beneficially own 309,948 shares of common stock, representing 3.60% of the class, based on 8,598,976 shares outstanding as of May 8, 2026. All 309,948 shares are held directly by Opaleye, L.P., with shared voting and dispositive power and no sole voting or dispositive power reported. The filing states this reflects ownership of 5 percent or less of the class and includes a joint filing agreement among the reporting persons.
BlackRock, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of SANUWAVE HEALTH INC. BlackRock reported beneficial ownership of 132,058 shares of common stock, representing 1.5% of the class as of this amendment.
BlackRock reported sole voting power and sole dispositive power over all 132,058 shares, with no shared voting or dispositive power. The filing notes that various persons may have rights to dividends or sale proceeds through BlackRock-managed accounts, but no such person holds more than five percent of SANUWAVE HEALTH INC’s outstanding common shares.
Sanuwave Health, Inc. reported preliminary, unaudited revenue for the quarter ended June 30, 2026 in the range of $9.6–$9.8 million, above the high end of its revised guidance of $8.5–$9.5 million. Preliminary Q2 2026 revenue is approximately 3–5% lower than the $10.1 million reported in the second quarter of 2025.
Management highlighted headwinds in capital equipment sales from customer financial stress and a growing secondary market for used Ultramist systems, while noting record revenues and unit sales for consumable applicators. The revenue figures are based on initial analysis and may change after the completion of quarter-end closing and review procedures.
SANUWAVE Health director Jeffrey Blizard received a grant of 5,524 stock options on June 30, 2026. The options have an exercise price of $10.0000 per share, are exercisable into 5,524 shares of common stock, and were fully vested at the grant date. Following this compensation-related award, Blizard holds 5,524 derivative securities with an expiration date of June 30, 2031, and no open-market purchases or sales were reported in this filing.
SANUWAVE Health director Ian D. Miller received a grant of stock options, giving him the right to acquire 6,215 shares of Common Stock. The options have an exercise price of $10.00 per share, were fully vested on the grant date, and expire on June 30, 2031. Following this award, he holds 6,215 derivative securities directly.
SANUWAVE Health, Inc. director Gregory Matthew Bazar received a grant of stock options as part of his compensation. He was awarded 5,524 options to buy Common Stock at an exercise price of $10.00 per share. The options were fully vested on the grant date and expire on June 30, 2031. Following this grant, he holds stock options for 5,524 underlying shares directly, with no shares reported as bought or sold in the market.
SANUWAVE Health director Tyler James received a new stock option grant. He was awarded options covering 5,524 shares of Common Stock at an exercise price of $10.0000 per share. The options were fully vested on the grant date and expire on June 30, 2031. Following this grant, he holds 5,524 derivative securities directly.
SANUWAVE Health, Inc. reported that Chief Executive Officer C. Frank Morgan received a grant of stock options covering 5,524 shares of common stock. The options have an exercise price of $10.0000 per share and expire on June 30, 2031. The filing states these options were fully vested on the grant date, and following this award he holds options for 5,524 underlying shares directly.
Sanuwave Health updated its outlook for the quarter ending June 30, 2026, now expecting second-quarter revenue between $8.5 million and $9.5 million, which is below the guidance discussed on its prior quarterly call.
The company cites worsening conditions in the capital equipment market for its Ultramist system, driven by widespread clawbacks of CMS reimbursement for skin substitutes and allografts. These clawbacks are pressuring wound care practices, leading to closures and a growing secondary market for used Ultramist systems that is weighing on new system sales.
Despite weaker capital equipment demand, Sanuwave reports that applicator and other consumable volumes remain strong and that it is on pace for a record quarterly unit volume of consumables in the second quarter. Management emphasizes a focus on supporting new users, especially those acquiring systems via the secondary market, and remains optimistic about its product pipeline and longer-term potential while acknowledging near-term challenges for capital sales.
Sanuwave Health, Inc. reported results from its 2026 annual stockholder meeting held on June 11, 2026. Stockholders elected five directors—Morgan Frank, Gregory Bazar, Jeffrey Blizard, Ian Miller and James Tyler—to serve until the 2027 annual meeting, with each nominee receiving more votes for than withheld.
Stockholders also ratified Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 6,057,957 votes for and limited opposition. In an advisory, non-binding vote, investors approved the compensation paid to the company’s named executive officers, with 4,666,444 votes for and 385,238 against.